| Autor: |
Mishra, Ameet K., Schmidt, Timothy M., Martell, Ella B., Chen, Alex S., Dogru, Reyna E., Hematti, Peiman, Callander, Natalie S. |
| Zdroj: |
Transplantation and Cellular Therapy; February 2024, Vol. 30 Issue: 2 p191-202, 12p |
| Abstrakt: |
•Despite an unprecedented response with anti-BCMA CAR-T therapy, the majority of patients will ultimately relapse.•The T cell compartments of patients with relapsed/refractory multiple myeloma (RRMM) differ from those of patients with normal bone marrow and patients with newly diagnosed multiple myeloma.•Novel double-negative CD3+T cells were found in RRMM and CAR-T relapsed cases.•Most T cells in RRMM, and significant subsets of T cells in post-CAR-T relapsed cases, expressed multiple coinhibitory markers, including PD1, TIGIT, 2B4, and KLRG1. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect